Exploring the Role of Biosimilars in Optimizing Treatment of Retinal Diseases

Undertreatment of nAMD and Implications for LongTerm Vision

David Brown, MD; Diana Do, MD; Peter Kaiser, MD; Neal Bressler, MD

Show Description +

A panel of retina specialists discuss the factors that lead to undertreatment of nAMD with anti-VEGF therapy in the real world.

Posted: 4/14/2023

Keywords:

Biogen

•

Neovascular Age-Related Macular Degeneration

•

Anti-VEGF

Up Next

Name: Undertreatment of nAMD and Implications for LongTerm Vision
Uploaded: 2023-04-14T20:53:35+00:00
Description: A panel of retina specialists discuss the factors that lead to undertreatment of nAMD with anti-VEGF therapy in the real world.

What Is a Biosimilar?

Peter Kaiser, MD

Biosimilars: Impact on Cost

Peter Kaiser, MD

Understanding Biosimilar Clinical Trials

Peter Kaiser, MD

Ranibizumab-nuna: Review of Clinical Trial Data

Neil Bressler, MD

A Deeper Look at Clinical Trial Outcomes

David Brown, MD; Diana Do, MD; Peter Kaiser, MD; Neal Bressler, MD

Adopting Bioimilars: Practical Considerations

David Brown, MD

Biosimilars: Health Economic Aspects

David Brown, MD

Biosimilars: Learning from Other Parts of Medicine

Diana Do, MD

What Does the Conversation Sound Like?

David Brown, MD

The Current Treatment Paradigm in nAMD

Diana Do, MD

Back to All Videos

Undertreatment of nAMD and Implications for LongTerm Vision

David Brown, MD; Diana Do, MD; Peter Kaiser, MD; Neal Bressler, MD

A panel of retina specialists discuss the factors that lead to undertreatment of nAMD with anti-VEGF therapy in the real world.

Posted: 4/14/2023

Keywords:

Biogen

•

Neovascular Age-Related Macular Degeneration

•

Anti-VEGF

Resources

Biosimilars in Retinal Disease Management

View Resource

About Biogen

One of the world’s first global biotechnology companies, Biogen, was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Biogen is commercializing biosimilars and transforming the standard of care for patients in several areas of high unmet need.

Follow Biogen